The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Related Articles
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia | NEJM
Whether fixed-duration acalabrutinib–venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocyti…
Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer: results of a phase Ib clinical trial
Ivonescimab is a humanized IgG1 bispecific anti-PD-1/VEGF antibody. This study aimed to evaluate the safety and tolerance of ivonescimab combined with etoposide and carboplatin as…
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer | NEJM
Neuregulin 1 (NRG1) fusions are recurrent oncogenic drivers found in multiple solid tumors. NRG1 binds to human epidermal growth factor receptor 3 (HER3), leading to…
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia | NEJM
Whether fixed-duration acalabrutinib–venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocyti…
Judge blocks Trump’s bid to restrict birthright citizenship
The ruling puts a hold on Trump’s executive order until the legal process plays out, which could take months or even years.
Review: Essential Thrombocythemia
This narrative review summarizes current evidence on the pathophysiology, clinical presentation and diagnosis, risk stratification, and treatment of essential thrombocythemia.
